Abstract: Radiolabeled antisense imaging may be defined as the detection of diseases through the administration of radiolabeled antisense oligonucleotide designed to bind in a sequence-specific manner to the machinery of translation or transcription. No immunogenity, low molecular weight of probes and easily penetrating the tumor cells are some of it's good aspects.Despite its good prospective, factors as selection of targeted serial, identification of ideal oligonucleotides are still roadblocks in developing antisense imaging. Many problems must be solved before in vivo application of antisense imaging, among those including in vivo stability, specific absorption and retention by targeted cells, nonspecific serum binding, and so on.